Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Circ Heart Fail. 2016 Aug;9(8):e003146. doi: 10.1161/CIRCHEARTFAILURE.116.003146

Figure 1.

Figure 1

Flow diagram of model development cohort selection and illness-death multistate model transitions. Selection of model development cohort and the number of participants with each of the illness-death multistate model transitions. HEAAL, Heart Failure Endpoint evaluation of Angiotensin II Antagonist Losartan; NYHA, New York Heart Association; HF, heart failure